多模态影像技术在脑血管病中的应用与前景 —— 以 CT、MRI 为核心的综合诊疗体系

Application and Prospect of Multimodal Imaging Technology in Cerebrovascular Diseases——A Comprehensive Diagnosis and Treatment System with CT and MRI as the Core

摘要:

多模式 CT 与 MRI 影像技术是脑血管病诊疗的核心工具，整合结构、功能及代谢信息，为疾病诊治提供全方位支持。多模式 CT 含平扫 CT（NCCT）、CT 血管成像（CTA）及 CT 灌注成像（CTP），扫描快速、普及率高：NCCT 可 快速检出急性颅内出血，CTA 精准识别大血管闭塞与动脉瘤，辅助血栓切除术决策，CTP 通过血流动力学参数区分梗死核心与缺血半暗带，指导溶栓治疗。多模式 MRI 具高软组织对比度、无辐射优势，包括弥散加权成像（DWI）、流体衰减反转恢复（FLAIR）等：DWI 数分钟内检测早期缺血，FLAIR 定量分析界定溶栓时间窗，磁共振血管成像（MRA）清晰显示微小血管病变。两者联合实现信息互补，显著提升急性缺血性卒中诊断准确率，为侧支循环评估、手术规划及预后预测提供关键依据。结合影像组学与人工智能，可进一步优化诊疗效率。此外，新型纳米探针、便携式 MRI 等技术创新，及与血清生物标志物的联合应用，为脑血管病精准医疗开辟新方向，有望突破现有诊疗局限，改善患者预后。

Abstract:

Multimodal CT and MRI imaging technologies stand as the cornerstone of cerebrovascular disease diagnosis and management, integrating structural, functional, and metabolic information to deliver comprehensive support for clinical decision-making throughout the disease journey. These technologies have revolutionized the clinical approach to conditions such as stroke, cerebral aneurysms, and vascular malformations—leading global causes of mortality and disability—by enabling early detection, precise assessment, and personalized treatment planning. Multimodal CT, characterized by rapid scanning (completable within 5-10 minutes), high accessibility, and robustness against motion artifacts, comprises non-contrast CT (NCCT), CT angiography (CTA), and CT perfusion imaging (CTP) as its core components, supplemented by advanced techniques like multi-detector row CT and spectral CT. NCCT serves as the frontline screening tool for acute cerebrovascular events, detecting acute intracranial hemorrhage with 100% sensitivity within 1 second and quantifying early ischemic changes via the ASPECTS scoring system. CTA achieves submillimeter spatial resolution, accurately identifying large vessel occlusions (LVOs) and intracranial aneurysms (with a detection sensitivity of 98.6%) to guide endovascular thrombectomy decisions, while its "spot sign" analysis predicts intracerebral hemorrhage expansion risk. CTP distinguishes the infarct core (irreversible damage, defined by rCBF < 30%) from the ischemic penumbra (salvageable tissue, indicated by Tmax > 6 seconds) through hemodynamic parameters, as validated by the DEFUSE-3 trial which showed a 19% improvement in 90-day functional independence with CTP-guided endovascular therapy. However, limitations include ionizing radiation exposure and potential nephrotoxicity from iodine contrast agents. Multimodal MRI offers superior soft tissue contrast and radiation-free imaging, encompassing diffusion-weighted imaging (DWI), fluid-attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and perfusion-weighted imaging (PWI). DWI detects cytotoxic edema within 30 minutes of ischemia onset with over 95% sensitivity, while ADC value quantification differentiates acute from subacute lesions. The DWI-FLAIR mismatch phenomenon reliably identifies wake-up strokes eligible for thrombolysis, and quantitative FLAIR signal intensity ratio (SIR ≤ 1.18) accurately defines the 4.5-hour thrombolysis time window. MRA, particularly 3T TOF-MRA, visualizes small vessel lesions with 92.3% consistency with DSA, and PWI-DWI mismatch identifies salvageable tissue, improving favorable outcomes by 22% according to meta-analyses. Advanced sequences like BOLD-fMRI, MRS, and SWI further enable functional localization, metabolic assessment, and microhemorrhage detection. Despite its advantages, MRI is limited by longer scan times (15-30 minutes), lower accessibility, and contraindications for patients with metallic implants. The integration of multimodal CT and MRI achieves complementary advantages, elevating the diagnostic accuracy of acute ischemic stroke to 96.7%. Clinical studies demonstrate that optimized MRI protocols can reduce door-to-needle time (DNT) to 61.23±9.32 minutes, outperforming traditional multimodal CT (87.22±14.26 minutes). Emerging innovations include multimodal nanoprobes (e.g., NanoGd) for dynamic neuroinflammation monitoring, portable MRI (0.064T) with 92.1% sensitivity for intracerebral hemorrhage detection in resource-limited settings, and the fusion of radiomics with artificial intelligence (AI)—which accelerates image analysis by up to 150-fold and enhances diagnostic precision. Future directions focus on standardizing scanning protocols, reducing MRI scan duration via compressed sensing, optimizing CT radiation doses, and integrating imaging with serum biomarkers (e.g., GFAP, NSE) to advance precision medicine. By overcoming current limitations, multimodal imaging technologies will continue to reshape cerebrovascular disease management, expanding treatment windows and improving patient outcomes.